However, IL-6 is also known to correlate with the malignancy potential of the tumor itself, such as in patients with advanced stage HCC or high AFP, and has been reported to contribute to shorter OS regardless of treatment [13, 14, 17]. This evidence concerns the gene AFP and neoplasm.